NDA 218490 · Actelion
Opsynvi
Macitentan, Tadalafil · Oral · Phosphodiesterase 5 Inhibitor; Endothelin Receptor Antagonist
OrphanLast checked: Nov 19, 2026Latest source record: Apr 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 22, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
66
26 Phase 3, 6 recruiting
FAERS reports
25
17 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: EMBRYO-FETAL TOXICITY OPSYNVI is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ]. Therefore, for females of reproductive potential, exclude pregnancy before the start of treatment with OPSYNVI. Advise use of effective contraception before the initiation of treatment, during treatment, and for one month after stopping treatment with OPSYNVI [see Dosage and Administration (2.2) , Use in Specific Populations (8.3) ]. When pregnancy is detected, discontinue OPSYNVI as soon as possible [see Warnings and Precautions (5.1) ] . WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Based on animal data, OPSYNVI may cause fetal harm if used during pregnancy ( 4.1 , 5.1 , 8.1 ). Females of reproductive...
What it is approved for
From the label in effect Apr 11, 2025.
OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II–III. ( 1.1 ) Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability. ( 1.1 , 14 ) 1.1 Pulmonary Arterial Hypertension OPSYNVI is the combination of macitentan and tadalafil indicated for the chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II–III). Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability [see Clinical Studies (14.1) ] .
Mechanism: Macitentan Endothelin (ET)-1 and its receptors (ETA and ETB) mediate a variety of deleterious effects, such as vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. In disease conditions such as PAH, the local ET system is upregulated and is involved in vascular hypertrophy and in organ damage. Macitentan is an endothelin receptor antagonist that inhibits the binding of ET-1 to both ETA and ETB receptors. Macitentan displays high affinity and sustained occupancy of the ET receptors in human pulmonary arterial smooth muscle cells. One of the metabolites of macitentan is...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2024 Original approval · Type 4 - New Combination OrphanLetterLabelMedication Guide
2 products under this application
- OPSYNVI · MACITENTAN 10MG; TADALAFIL 40MG · TABLET, ORAL · Prescription
- OPSYNVI · MACITENTAN 10MG; TADALAFIL 20MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Macitentan" as an intervention, any sponsor and status, largest first.
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00660179 · 742 participants · Start May 2008 · Primary completion Mar 2012
Drug: macitentan (ACT-064992); macitentan (ACT-064992) and 1 more · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Pheonix, Arizona; Los Angeles, California · 153 sites in all
- Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00667823 · 550 participants · Start Oct 17, 2008 · Primary completion Dec 7, 2020
Drug: Macitentan · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 158 sites in all
- Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01474109 · 289 participants · Start Dec 2011 · Primary completion Nov 2013
Drug: macitentan 3mg; macitentan 10mg and 1 more · For: Systemic Sclerosis; Ulcers
Sites: Tucson, Arizona; Los Angeles, California; Aventura, Florida · 77 sites in all
- Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT InstrumentPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01841762 · 284 participants · Start Apr 1, 2013 · Primary completion Nov 1, 2015
Drug: Macitentan · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Phoenix, Arizona; Beverly Hills, California · 81 sites in all
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionPivotal-lookingRecruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT05179876 · 280 participants (planned) · Start May 4, 2022 · Primary completion Jan 31, 2027
Drug: Macitentan; Selexipag and 1 more · For: Hypertension, Pulmonary
Sites: Minsk, Belarus; Leuven, Belgium; Sofia, Bulgaria · 45 sites in all
- Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis PatientsPivotal-lookingTerminated
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT01474122 · 265 participants · Start Dec 2011 · Primary completion Feb 2014
Drug: Macitentan 3 mg; Macitentan 10 mg and 1 more · For: Digital Ulcers
- The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial HypertensionPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT02558231 · 247 participants · Start May 1, 2016 · Primary completion Aug 29, 2019
Drug: Macitentan; Tadalafil and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea4
- cough3
- death3
- diarrhoea3
- chest pain2
- drug intolerance2
- hypotension2
- pneumonia2
- adverse event1
- angiopathy1
- arthritis1
- atrial fibrillation1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 3 |
| 2025 | 16 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Opsynvi (Macitentan/Tadalafil)
2024 spending
$24.5M
Beneficiaries
536
1,875 claims
Per beneficiary
$45,659
$423.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $24,473,218 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E, Jansa P, Fan F, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Multicenter Study
- Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, et al. · N Engl J Med 2013 · Clinical Trial, Phase III, Multicenter Study
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, et al. · J Am Coll Cardiol 2021 · Clinical Trial, Phase III, Comparative Study
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial.
Berger RMF, Dunbar Ivy D, Borissoff JI, et al. · J Pediatr 2026 · Randomized Controlled Trial, Multicenter Study
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.
McLaughlin VV, Hoeper MM, Channick RN, et al. · J Am Coll Cardiol 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.